Juxtapid Capsule
NDC Package 76431-110-01
Package Information
Juxtapid (lomitapide mesylate) capsules is jUXTAPID is contraindicated in the following conditions:Pregnancy [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1)].Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6), Drug Interactions (7.1), and Clinical Pharmacology (12.3)].Patients with moderate or severe hepatic impairment (based on Child-Pugh category B or C) and patients with active liver disease, including unexplained persistent elevations of serum transaminases [see Warnings and Precautions (5.1) and Use in Specific Populations (8.7)]. This formulation utilizes a capsule delivery system. Marketed by Amryt Pharmaceuticals Dac, this product is identified by NDC 76431-110 and is authorized under FDA application NDA203858.
Identification & Billing
- RxCUI: 1364484 - lomitapide 10 MG Oral Capsule
- RxCUI: 1364484 - lomitapide (as lomitapide mesylate) 10 MG Oral Capsule
- RxCUI: 1364490 - Juxtapid 10 MG Oral Capsule
- RxCUI: 1364490 - lomitapide 10 MG Oral Capsule [Juxtapid]
- RxCUI: 1364490 - Juxtapid (as lomitapide mesylate) 10 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 76431 - Amryt Pharmaceuticals Dac
- 76431-110 - Juxtapid
- 76431-110-01 - 28 CAPSULE in 1 BOTTLE
- 76431-110 - Juxtapid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 76431-110-01 identifies a specific commercial package of 28 capsule in 1 bottle of Juxtapid, a human prescription drug labeled by Amryt Pharmaceuticals Dac. This product is billed for "EA" each discreet unit and contains an estimated amount of 28 billable units per package. This capsule is formulated for oral use and contains lomitapide mesylate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amryt Pharmaceuticals Dac on January 03, 2013.
How is this Amryt Pharmaceuticals Dac product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 76431011001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 28 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.